Climb Bio, Inc. (CLYM) Stock Grade

About Climb Bio, Inc.'s fundamentals

Climb Bio is a biotechnology company with a market capitalization of $271.2 million that reported no revenue growth year-over-year and generated no net income in its latest annual period, instead posting a net loss. The company does not currently pay dividends and lacks profitability metrics such as a P/E ratio and return on equity. As an early-stage biotech firm, Climb Bio is in a development phase typical of companies in this sector that have not yet achieved commercial revenue generation.